The WHO classification continues to highlight the importance of genetic mutations, particularly those that are commonly associated with therapy-related neoplasms, such as TP53, RUNX1, complex karyotypes, and specific translocations and deletions (e.g., t(6;9), t(9;11)), and deletions (e.g., del(5q), del(7q)) are associated with secondary myeloid neoplasms and are integrated into the classification scheme. Here, RUNX1 is linked to myeloid neoplasm.